Drugs / Nesuparib
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07570186 | May → Jul 2026 overdue | — | Onconic Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04335604 | Dec 2017 → Dec 2021 | cancer | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07364422 | Feb 2026 overdue | gastric cancer | Onconic Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05257993 | Mar 2022 → Apr 2030 expected | pancreatic ductal adenocarcinoma | Onconic Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07370818 | Feb 2026 → Dec 2029 expected | ovarian cancer | Onconic Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06502743 | Sep 2024 → Dec 2027 expected | endometrial carcinoma | Yonsei University | Recruiting | No outcome recorded |
| Phase 2 | NCT05475184 | Aug 2022 → Nov 2024 overdue | ovarian cancer | Onconic Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nesuparib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06502743 ↗ |
| Known as | JPI-547 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07370818 ↗ |
| Known as | NOV140201 | “A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors” NCT04335604 ↗ |
| Action | Inhibit | “a Dual Inhibitor of PARP/TNK” NCT04335604 ↗ |
| Modality | Small molecule | — CHEMBL5095245 ↗ |
| Route | Oral | “The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).” NCT05257993 ↗ |
| Target | PARP1 | “PARP1/2 and tankyrase 1/2 inhibitor” PMID 41514313 ↗ Dec 2025 |